Evidence map›Paper›PMID 36091039›Full record

ArticleFrontiers in immunology2022

Differential distribution and prognostic value of CD4

Zhi-Yong Shi, Sheng-Xiao Zhang, Cai-Hong Li, Di Fan, Yan Xue, Zhe-Hao Cheng, Li-Xiang Wu, Ke-Yi Lu, Zhi-Fang Wu, Xiao-Feng Li and 2 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in immunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Observational
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Zhi-Yong ShiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Sheng-Xiao ZhangDepartment of Rheumatology, Second Hospital of Shanxi Medical University, Taiyuan, China.
Cai-Hong LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Di FanDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Yan XueDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Zhe-Hao ChengDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Li-Xiang WuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Ke-Yi LuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Zhi-Fang WuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Xiao-Feng LiDepartment of Rheumatology, Second Hospital of Shanxi Medical University, Taiyuan, China.
Hai-Yan LiuDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Si-Jin LiDepartment of Nuclear Medicine, First Hospital of Shanxi Medical University, Taiyuan, China.
Shanxi Medical University · CNFirst Hospital of Shanxi Medical University · CNSecond Hospital of Shanxi Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Differentiated thyroid cancer is the most frequently diagnosed endocrine tumor. While differentiated thyroid cancers often respond to initial treatment, little is known about the differences in circulating immune cells amongst patients who respond differently. A prospective study of 39 patients with differentiated thyroid cancer was conducted. Serum thyroglobulin levels and thyroid and immunological functions were tested before and after radioactive iodine treatment (RAIT). Efficacy assessments were performed 6 to 12 months after radioactive iodine treatment. Most patients showed an excellent response to radioactive iodine treatment. Before radioactive iodine treatment, the excellent response group had considerably fewer circulating CD4

Indexed as

AdenocarcinomaThyroid NeoplasmsCD4-Positive T-LymphocytesHumansIodine RadioisotopesPrognosisProspective StudiesT-Lymphocyte SubsetsIodine RadioisotopesCD4+ T cell subsetsdifferentiated thyroid cancerefficacy assessmentprognosisradioactive iodine therapy

Identifiers

PMID36091039
PMCPMC9459039
OpenAlexW4293199827

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.